February 12, 2021
Bayer, the maker of Roundup weed killer, has agreed to increase the compensation the company will pay to resolve future non-Hodgkin’s lymphoma claims to $2 billion, after announcing an initial proposal last year that would have set aside $1.25 billion for future cases alleging that Roundup causes… Read More> Comments Off on Bayer Increases Payout for Future Roundup Cancer Claims to $2 Billion
August 26, 2020
Bayer, the maker of the female sterilization device Essure, announced last week that it would pay about $1.6 billion to resolve approximately 90% of the nearly 39,000 U.S. Essure claims involving women who allegedly suffered injuries caused by the controversial birth control device. The German medical device… Read More> Comments Off on Bayer Agrees to Settle Essure Injury Lawsuits for $1.6 Billion
June 26, 2020
Bayer, the maker of the highly controversial Roundup weed killer, has announced a plan to settle most of the Roundup cancer lawsuits currently pending against the company, as well as possible future claims, for more than $10 billion. The announcement came on June 24, 2020, after… Read More> Comments Off on Bayer Will Pay $10 Billion to Resolve Tens of Thousands of Roundup Cancer Claims
June 4, 2020
The surviving family member of a Pennsylvania man who died from pancreatic cancer last year has filed a wrongful death lawsuit against the makers of Zantac, alleging that years of exposure to carcinogenic chemicals in the recalled heartburn drug caused her loved one’s death. The Zantac wrongful… Read More> Comments Off on Family Sues Zantac Makers Over Fatal Case of Pancreatic Cancer
May 14, 2020
The federal judge overseeing the Zantac multidistrict litigation (MDL) has chosen more than two dozen plaintiffs’ attorneys to serve in leadership positions in the growing litigation over the recalled heartburn drug Zantac and its potential to cause cancer in users. After interviewing 62 attorneys involved in the… Read More> Comments Off on Federal Judge Assigns More Than Two Dozen Attorneys to Leadership Positions in Zantac Cancer MDL
May 13, 2020
A California appeals court has reinstated the eligibility of thousands of cases against Johnson & Johnson and its Janssen Pharmaceuticals subsidiary, alleging that the company’s antipsychotic drug Risperdal causes abnormal breast growth in males. The court ruling reverses a lower court’s decision to grant Johnson & Johnson’s… Read More> Comments Off on Appeals Court Reinstates Risperdal Gynecomastia Claims Against Johnson & Johnson
May 12, 2020
A recent ruling from a federal judge in New Jersey has cleared the way for thousands of talcum powder cancer lawsuits against Johnson & Johnson to proceed. The ruling, handed down by U.S. District Judge Freda L. Wolfson, allows testimony from plaintiffs’ medical and scientific experts, including… Read More> Comments Off on Daubert Ruling Green Lights 16,000 Talcum Powder Cases Against Johnson & Johnson
